newsfilter
← Latest News
PR Newswire·

INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights

INO
  • The FDA granted accelerated approval on October 30, 2026, for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) to reduce surgical frequency in adults with Recurrent Respiratory Papillomatosis (RRP).
  • VOCERYQ is the first FDA-approved DNA medicine, validating INOVIO's novel platform technology.
  • The drug is expected to be available for order and ship approximately 60 days post-approval, with a full commercial launch scheduled for the first quarter of 2027.
  • VOCERYQ approval was based on a complete response defined as no surgical intervention required in the 12 months following treatment, supported by data from the RRP-001 study involving 32 adult patients.
  • A confirmatory study is planned to verify clinical benefit, with a draft protocol submission to the FDA expected by the end of 2026.
  • INOVIO plans to submit for conditional marketing authorization in Europe before the end of 2026.
  • A recently completed public offering generated $80.5 million in net proceeds to support the commercial launch of VOCERYQ.
  • Third quarter 2026 R\&D expenses decreased to $10.6 million, while SG\&A expenses increased to $9.2 million due to anticipated VOCERYQ launch activities.
  • INOVIO reported a net loss of $49.2 million for the three months ended September 30, 2026, primarily driven by a $26.9 million non-cash loss on warrant liability fair value adjustments.
  • Cash, cash equivalents, and short-term investments stood at $48.4 million as of September 30, 2026, excluding the $80.5 million from the November 2026 offering.
  • INOVIO estimates its current cash resources will support operations into late Q4 2027, extending past the VOCERYQ launch.
  • INOVIO is advancing next-generation DNA-Encoded Protein (DPROT) programs for rare diseases such as Hemophilia A, Fabry Disease, Hypophosphatasia, with potential partnerships to accelerate development.
  • The company hosted a conference call on November 10, 2026, at 4:30 PM ET to discuss third quarter 2026 financial results and business updates.
Company
INOVIO Pharmaceuticals, Inc.
Keywords
INOVIO Pharmaceuticals, Inc.